Regeneron Pharmaceuticals News

Northern, WI 2/13/12 - Shares of Regeneron Pharmaceuticals Inc. jumped Monday after the company predicted much stronger sales of its eye drug Eylea.

Analysts at Brean Murray upped their price target on shares of Regeneron Pharms from $100.00 to $120.00 in a research report issued to clients and investors on Monday.

Regeneron Pharmaceuticals, Inc. Announces February 13, 2012 as Date of Full Year 2011 Financial and Operating Results Conference Call and Webcast Live audio of the conference call will be webcast online simultaneously.

Regeneron Pharmaceuticals Inc. surged in early trading after the company increased its sales forecast for eye drug Eylea higher than analyst estimates.

Shares of the following companies are having unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 9:35 a.m. in New York.

The Company reported total revenues of $123.0 million for the fourth quarter and $445.8 million for the year ended December 31, 2011.

The Company will host a conference call at 8:30 AM EST that day. The February 13, 2012 date is a change from the previously announced date of February 16, 2012.

Perhaps it is true that any press is good press. No one likes bad press, especially when others in the same field are receiving positive press.

Visa Inc. : Visa announced that U.S. financial institutions have reported issuing an estimated one million Visa-branded, EMV chip-enabled cards as of Dec.

Analysts at BMO Capital Markets downgraded PNC Financial Services Group Inc from "outperform" to "market perform." PNC's shares closed at $62.20 on Friday.

Jefferies Group increased their price target on shares of Regeneron Pharms to $1,111.00 in a research note issued on Monday.

Piper Jaffray lowers it rating on Regeneron Pharmaceuticals to Neutral from Overweight as shares appear over-extended as the stock has overperformed peers year to date.

JPMorgan Chase & Co. and Citigroup Inc. fell. Regeneron Pharmaceuticals Inc. dropped 2.9 percent after the stock was downgraded at Piper Jaffray & Co.

Equities research analysts at ThinkEquity initiated coverage on shares of Regeneron Pharms in a research note issued to investors on Friday.

Peabody Energy Corp. : BMO Capital reduced its target on Peabody Energy after the company provided significantly lower than expected Q1 EPS guidance.

Yum! Brands : Yum! Brands CEO, David Novak, has managed to turn millions of Chinese into ardent fans of Kentucky-style 'finger-lickin good' chicken, Barron's reports.

Regeneron Pharms was upgraded by Bank of America to a "buy" rating in a research note issued on Monday.

The Company will host a conference call at 8:30 AM EST that day. Live audio of the conference call will be webcast online simultaneously.

Interested in the defensive sector of healthcare stocks? If so, here are some ideas to get started on your search.

A Wall Street analyst who says investors should buy shares of Regeneron Pharmaceuticals dismissed concerns raised by another company in an interview with Forbes that Regeneron's new cholesterol drug targeting PCSK9 could be delayed.